Results 181 to 190 of about 277,288 (290)

Prognostic Value of the TLM3 Biomarker Panel for Early Fibrosis Development in MASLD Within the General Population. [PDF]

Liver Int
van Son KC, de Jong JCBC, Özsezen S, Caspers MPM, Augustijn QJJ, Snabel J, Galenkamp H, Hamer HM, van Dijk AM, van Koppen A, Mak AL, van den Born BJ, Nieuwdorp M, Drenth JPH, Gluud LL, Tushuizen ME, Hanemaaijer R, Verschuren L, Holleboom AG.   +18 more
europepmc   +1 more source

Woordenboek van Droogeryen van den Heer M. N. Beels vervolgt door Meylink. Amsterdam by G. J. A. Beyrinck 1845 [PDF]

du Mênil
openalex   +1 more source

Expedited Approval in Oncology: A Study of European Regulators' Perspectives and Trade‐Offs

Clinical Pharmacology &Therapeutics, EarlyView.
The purpose of this study was to describe the perspectives and trade‐offs of EU regulators about expedited approvals for treatments of patients with advanced cancer. The study consisted of a cross‐sectional survey with assessors and experts from the network of the European Medicines Agency (EMA).
Francesco Pignatti, Filip Josephson, Pierre Demolis, Olli Tenhunen, Elias Péan, Douwe Postmus   +5 more
wiley   +1 more source

Introduction

Cardiovascular Innovations and Applications, 2016
Ezra A. Amsterdam
doaj   +1 more source

Adult prognosis of childhood kidney replacement therapy: ERA Registry Figure of the Month. [PDF]

Clin Kidney J
Stel VS, Ortiz A, Kramer A.
europepmc   +1 more source

Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX‐FP Prophylaxis in Hemophilia B: A Repeated Time‐to‐Event Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
In hemophilia B, pharmacokinetic (PK)‐guided dosing of extended half‐life factor IX (EHL‐FIX) concentrates can secure targeted FIX exposure. Target FIX activity levels in plasma should be individually set primarily taking bleeding tendency into account, alongside the presence of target joints, physical activity, and preferred dosing schedules. In other
Sjoerd F. Koopman, Marjon H. Cnossen, Ron A.A. Mathot, on behalf of the OPTI‐CLOT study group and SYMPHONY consortium, S. H. Reitsma   +4 more
wiley   +1 more source

Effectiveness and Safety of Personalized Cholic Acid Treatment in Patients With Bile Acid Synthesis Defects. [PDF]

J Inherit Metab Dis
Polak Y, Kemper EM, Engelen M, Klouwer FCC, Berendse K, Vaz FM, Koot BGP, Swart ENL, Hollak CEM.   +8 more
europepmc   +1 more source

I. N. Sneddon, Mixed Boundary Value Problems in Potential Theory (North-Holland Publishing Company—Amsterdam, 1966), viii+282 pp., 80s. [PDF]

, 1968
J. C. Cooke
openalex   +1 more source

Optimizing Patient Registries for Regulatory Decision Making ‐ Key Learnings From an HMA/EMA Multistakeholder Workshop

Clinical Pharmacology &Therapeutics, EarlyView.
The Joint Heads of Medicines Agencies and European Medicines Agency's (HMA/EMA) big data initiative paves the way for better integration of real‐world data, including data from patient registries, into regulatory decisions on medicines. This article focuses on the outcome of a two‐day multistakeholder workshop organized by EMA in 2024, which explored ...
Kelly Plueschke, Carla Jonker, Hanna Kankanen, Thorsten Vetter, Bruno Sepodes, Lutz Naehrlich, Jan Hillert, Gracy Crane, Sabine Straus, Paolo Foggi, Simona Martin, Christina Kyriakopoulou, Peter Mol, Francesca Day, Kieran Breen, Neil Bennett, Mencia de Lemus Belmonte, Simon Bennett, Patrice Verpillat, Kit C. B. Roes, Ana Cochino, Franz Schaefer, Jesús María Hernández‐Rivas, Patricia McGettigan, Peter Arlett   +24 more
wiley   +1 more source

Performances touristiques et production des identités spatiales individuelles à Amsterdam

Carnets de Géographes, 2013
Amandine Chapuis
doaj   +1 more source